Search International and National Patent Collections
|1. (WO2018104893) ALPHA4-BETA7 ANTIBODIES WITH INCRASED FCRN BINDING AND/OR HALF-LIFE|
|Applicants:||GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
JOHNS, Brian Alvin
GOUGH, Gerald Wayne
|Title:||ALPHA4-BETA7 ANTIBODIES WITH INCRASED FCRN BINDING AND/OR HALF-LIFE|
The invention relates to novel α4β7antigen binding proteins. In particular, the invention relates to modified antigen binding proteins that are novel variants of anti-a4(37 antibodies, such as vedolizumab, which show increased binding to the FcRn receptor and/or increased half-life as compared to vedolizumab. Vedolizumab is an IgG1 monoclonal antibody comprising the light chain sequence of SEQ ID No: 7 and heavy chain sequence of SEQ ID No: 8. Methods as described herein comprise administering ART using compounds disclosed in Figure 4 and administering a modified antigen binding protein, for example a modified IgG α4β7 antibody such as a modified vedolizumab, having a variant Fc region with increased affinity to FcRn compared to unmodified antibody, resulting in sustained virologic control of the HIV infection in the subject - i.e. resulting in a cure or functional cure of the HIV infection in the subject.